PDCD1 and ovarian cancer: In a phase II clinical study of nivolumab (an anti-programmed cell death 1 antibody) involving patients with platinum-resistant recurrent ovarian cancer, Hamanishi et al. reported that 2 of 20 patients achieved complete response.